BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, Petronini PG. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J Exp Clin Cancer Res 2018;37:72. [PMID: 29587820 DOI: 10.1186/s13046-018-0741-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Barbosa AM, Martel F. Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds. Cancers (Basel) 2020;12:E154. [PMID: 31936350 DOI: 10.3390/cancers12010154] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
2 Li JY, Sun F, Zhou HF, Yang J, Huang C, Fan H. A Systematic Review Exploring the Anticancer Activity and Mechanisms of Glucomannan. Front Pharmacol 2019;10:930. [PMID: 31507423 DOI: 10.3389/fphar.2019.00930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
3 Bayer AL, Pietruska J, Farrell J, Mcree S, Alcaide P, Hinds PW. AKT1 Is Required for a Complete Palbociclib-Induced Senescence Phenotype in BRAF-V600E-Driven Human Melanoma. Cancers 2022;14:572. [DOI: 10.3390/cancers14030572] [Reference Citation Analysis]
4 Bonelli M, Terenziani R, Zoppi S, Fumarola C, La Monica S, Cretella D, Alfieri R, Cavazzoni A, Digiacomo G, Galetti M, Petronini PG. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells. Int J Mol Sci 2020;21:E5165. [PMID: 32708306 DOI: 10.3390/ijms21145165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Bömer M, Pérez-Salamó I, Florance HV, Salmon D, Dudenhoffer JH, Finch P, Cinar A, Smirnoff N, Harvey A, Devoto A. Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR. New Phytol 2021;229:2120-34. [PMID: 33124043 DOI: 10.1111/nph.17031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Uzhachenko RV, Bharti V, Ouyang Z, Blevins A, Mont S, Saleh N, Lawrence HA, Shen C, Chen SC, Ayers GD, DeNardo DG, Arteaga C, Richmond A, Vilgelm AE. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep 2021;35:108944. [PMID: 33826903 DOI: 10.1016/j.celrep.2021.108944] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chaudhary S, Pothuraju R, Rachagani S, Siddiqui JA, Atri P, Mallya K, Nasser MW, Sayed Z, Lyden ER, Smith L, Gupta SD, Ralhan R, Lakshmanan I, Jones DT, Ganti AK, Macha MA, Batra SK. Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring. Cancer Lett 2021;510:79-92. [PMID: 33878394 DOI: 10.1016/j.canlet.2021.04.004] [Reference Citation Analysis]
8 Zhang B, Li D, Jin X, Zhang K. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma. The International Journal of Biochemistry & Cell Biology 2020;128:105859. [DOI: 10.1016/j.biocel.2020.105859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer 2020;6:19. [PMID: 32550264 DOI: 10.1038/s41523-020-0160-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Niu Y, Xu J, Sun T. Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. J Cancer 2019;10:5504-17. [PMID: 31632494 DOI: 10.7150/jca.32628] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
11 Xie Y, Wang Y, Xiang W, Wang Q, Cao Y. Molecular Mechanisms of the Action of Myricetin in Cancer. Mini Rev Med Chem 2020;20:123-33. [PMID: 31648635 DOI: 10.2174/1389557519666191018112756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Santiappillai NT, Abuhammad S, Slater A, Kirby L, McArthur GA, Sheppard KE, Smith LK. CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway. Cancers (Basel) 2021;13:524. [PMID: 33572972 DOI: 10.3390/cancers13030524] [Reference Citation Analysis]
13 Cayo A, Segovia R, Venturini W, Moore-Carrasco R, Valenzuela C, Brown N. mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership. Int J Mol Sci 2021;22:8149. [PMID: 34360912 DOI: 10.3390/ijms22158149] [Reference Citation Analysis]
14 Bonelli M, La Monica S, Fumarola C, Alfieri R. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. Biochem Pharmacol 2019;170:113676. [PMID: 31647925 DOI: 10.1016/j.bcp.2019.113676] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
15 Alexandrou S, George SM, Ormandy CJ, Lim E, Oakes SR, Caldon CE. The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. Int J Mol Sci 2019;20:E667. [PMID: 30720718 DOI: 10.3390/ijms20030667] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lorito N, Bacci M, Smiriglia A, Mannelli M, Parri M, Comito G, Ippolito L, Giannoni E, Bonechi M, Benelli M, Migliaccio I, Malorni L, Chiarugi P, Morandi A. Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib.. Cells 2020;9:E668. [PMID: 32164162 DOI: 10.3390/cells9030668] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
17 Cretella D, Fumarola C, Bonelli M, Alfieri R, La Monica S, Digiacomo G, Cavazzoni A, Galetti M, Generali D, Petronini PG. Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Sci Rep 2019;9:13014. [PMID: 31506466 DOI: 10.1038/s41598-019-49484-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
18 Uras IZ, Maurer B, Nebenfuehr S, Zojer M, Valent P, Sexl V. Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. Int J Mol Sci 2018;19:E3987. [PMID: 30544932 DOI: 10.3390/ijms19123987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kietzman WB, Graham GT, Ory V, Sharif GM, Kushner MH, Gallanis GT, Kallakury B, Wellstein A, Riegel AT. Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer. Mol Cancer Ther 2019;18:2220-32. [PMID: 31451564 DOI: 10.1158/1535-7163.MCT-19-0231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 He J, McLaughlin RP, van der Noord V, Foekens JA, Martens JWM, van Westen G, Zhang Y, van de Water B. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer. Breast Cancer Res Treat 2019;178:263-74. [PMID: 31388935 DOI: 10.1007/s10549-019-05380-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
21 Hendrychová D, Jorda R, Kryštof V. How selective are clinical CDK4/6 inhibitors? Med Res Rev 2021;41:1578-98. [PMID: 33300617 DOI: 10.1002/med.21769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Sevgin B, Coban MN, Rencuzogullari Ö, Coker-gurkan A, Obakan-yerlikaya P, Uysal Onganer P, Arisan ED. AMPK Is the Crucial Target for the CDK4/6 Inhibitors Mediated Therapeutic Responses in PANC-1 and MIA PaCa-2 Pancreatic Cancer Cell Lines. Stresses 2021;1:48-68. [DOI: 10.3390/stresses1010005] [Reference Citation Analysis]
23 Conroy LR, Lorkiewicz P, He L, Yin X, Zhang X, Rai SN, Clem BF. Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells. Cancer Cell Int 2020;20:280. [PMID: 32624705 DOI: 10.1186/s12935-020-01357-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Han Y, Wang J, Wang Z, Xu B. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. Current Problems in Cancer 2020;44:100606. [DOI: 10.1016/j.currproblcancer.2020.100606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Yamamoto T, Kanaya N, Somlo G, Chen S. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer. Breast Cancer Res Treat 2019;174:615-25. [PMID: 30607633 DOI: 10.1007/s10549-018-05104-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
26 Tilekar K, Upadhyay N, Iancu CV, Pokrovsky V, Choe JY, Ramaa CS. Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer. Biochim Biophys Acta Rev Cancer. 2020;1874:188457. [PMID: 33096154 DOI: 10.1016/j.bbcan.2020.188457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
27 Du Q, Guo X, Wang M, Li Y, Sun X, Li Q. The application and prospect of CDK4/6 inhibitors in malignant solid tumors. J Hematol Oncol 2020;13:41. [PMID: 32357912 DOI: 10.1186/s13045-020-00880-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
28 Saleh L, Wilson C, Holen I. CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. MedComm (2020) 2021;2:514-30. [PMID: 34977868 DOI: 10.1002/mco2.97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Occhipinti G, Romagnoli E, Santoni M, Cimadamore A, Sorgentoni G, Cecati M, Giulietti M, Battelli N, Maccioni A, Storti N, Cheng L, Principato G, Montironi R, Piva F. Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications. Front Genet 2020;11:349. [PMID: 32351542 DOI: 10.3389/fgene.2020.00349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Rihawi K, Alfieri R, Fiorentino M, Fontana F, Capizzi E, Cavazzoni A, Terracciano M, La Monica S, Ferrarini A, Buson G, Petronini PG, Ardizzoni A. MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report. Transl Oncol 2019;12:116-21. [PMID: 30290287 DOI: 10.1016/j.tranon.2018.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
31 Sheng J, Kohno S, Okada N, Okahashi N, Teranishi K, Matsuda F, Shimizu H, Linn P, Nagatani N, Yamamura M, Harada K, Horike SI, Inoue H, Yano S, Kumar S, Kitajima S, Ajioka I, Takahashi C. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy. Hepatology 2021. [PMID: 33931882 DOI: 10.1002/hep.31872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Rencuzogulları O, Yerlikaya PO, Gürkan AÇ, Arısan ED, Telci D. Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells. J Cell Biochem 2020;121:508-23. [PMID: 31264276 DOI: 10.1002/jcb.29249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
33 Digiacomo G, Fumarola C, La Monica S, Bonelli MA, Cretella D, Alfieri R, Cavazzoni A, Galetti M, Bertolini P, Missale G, Petronini PG. Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. Front Oncol 2020;10:563249. [PMID: 33072590 DOI: 10.3389/fonc.2020.563249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Hu Y, Gao J, Wang M, Li M. Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. Cancer Manag Res 2021;13:5223-37. [PMID: 34234565 DOI: 10.2147/CMAR.S310649] [Reference Citation Analysis]
35 Johnson TI, Minteer CJ, Kottmann D, Dunlop CR, Fernández SBQ, Carnevalli LS, Wallez Y, Lau A, Richards FM, Jodrell DI. Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach. EBioMedicine 2021;68:103396. [PMID: 34049239 DOI: 10.1016/j.ebiom.2021.103396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Sager RA, Backe SJ, Ahanin E, Smith G, Nsouli I, Woodford MR, Bratslavsky G, Bourboulia D, Mollapour M. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nat Rev Urol 2022. [PMID: 35264774 DOI: 10.1038/s41585-022-00571-8] [Reference Citation Analysis]
37 Liao M, Zhang J, Wang G, Wang L, Liu J, Ouyang L, Liu B. Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. J Med Chem 2021;64:2382-418. [PMID: 33650861 DOI: 10.1021/acs.jmedchem.0c01180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]